MGI’s propriety DNBSEQ technology enable genomics unlimited and affordable. Compared to other existing sequencing platforms, DNBSEQ sequencing technology combines the advantages from low amplification error rates from DNBs and high density patterned arrays. These advantages dramatically improve sequencing accuracy, and have much lower duplication rates in WGS/WES applications.

In the presentation, Dr. Yuan Li, Product Manager at MGI, will introduce the MGI unique technologies and product portfolio including sample preparation, sequencing platform and bioinformatics solutions. Case study of cancer research, COVID-19 sequencing and single cell based on DNBSEQ will also be shared.